Tumour angiogenesis: Hitting cancer where it hurts

Kavitha Sunassee; Richard Vile

doi:10.1016/s0960-9822(06)00137-0

Tumour angiogenesis: Hitting cancer where it hurts

Kavitha Sunassee, Richard Vile

Molecular Medicine

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Two recent studies that involve perturbing tumour blood supply provide new hope for anti-cancer therapies. The first uses elegant molecular engineering to achieve tumour-specific blood clots and the second reports the identification of a natural inhibitor, endostatin, which is produced from tumour extracellular matrix.

Original language	English (US)
Pages (from-to)	R282-R285
Journal	Current Biology
Volume	7
Issue number	5
DOIs	https://doi.org/10.1016/s0960-9822(06)00137-0
State	Published - May 1 1997

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)
Agricultural and Biological Sciences(all)

Access to Document

10.1016/s0960-9822(06)00137-0

Cite this

@article{f3047a5f58e84c2cb400928890d93ad8,

title = "Tumour angiogenesis: Hitting cancer where it hurts",

abstract = "Two recent studies that involve perturbing tumour blood supply provide new hope for anti-cancer therapies. The first uses elegant molecular engineering to achieve tumour-specific blood clots and the second reports the identification of a natural inhibitor, endostatin, which is produced from tumour extracellular matrix.",

author = "Kavitha Sunassee and Richard Vile",

year = "1997",

month = may,

day = "1",

doi = "10.1016/s0960-9822(06)00137-0",

language = "English (US)",

volume = "7",

pages = "R282--R285",

journal = "Current Biology",

issn = "0960-9822",

publisher = "Cell Press",

number = "5",

}

TY - JOUR

T1 - Tumour angiogenesis

T2 - Hitting cancer where it hurts

AU - Sunassee, Kavitha

AU - Vile, Richard

PY - 1997/5/1

Y1 - 1997/5/1

N2 - Two recent studies that involve perturbing tumour blood supply provide new hope for anti-cancer therapies. The first uses elegant molecular engineering to achieve tumour-specific blood clots and the second reports the identification of a natural inhibitor, endostatin, which is produced from tumour extracellular matrix.

AB - Two recent studies that involve perturbing tumour blood supply provide new hope for anti-cancer therapies. The first uses elegant molecular engineering to achieve tumour-specific blood clots and the second reports the identification of a natural inhibitor, endostatin, which is produced from tumour extracellular matrix.

UR - http://www.scopus.com/inward/record.url?scp=0030904086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030904086&partnerID=8YFLogxK

U2 - 10.1016/s0960-9822(06)00137-0

DO - 10.1016/s0960-9822(06)00137-0

M3 - Article

C2 - 9115387

AN - SCOPUS:0030904086

SN - 0960-9822

VL - 7

SP - R282-R285

JO - Current Biology

JF - Current Biology

IS - 5

ER -

Tumour angiogenesis: Hitting cancer where it hurts

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this